Who is sponsoring NCT03700437?

NCT03700437 is sponsored by Indiana University.

What drugs are being tested in NCT03700437?

Interventions in NCT03700437: Fasting-Mimicking Diet.

What condition does NCT03700437 study?

NCT03700437 studies Non-small Cell Lung Cancer.

Is NCT03700437 still recruiting?

NCT03700437 is currently completed. Last updated 12 May 2022.

Last reviewed 2022-05-12 · How we verify

NCT03700437

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fasting-mimicking Diet With Chemo-immunotherapy in Non-small Cell Lung Cancer (NSCLC)

Completed NA Last updated 12 May 2022

What this trial tests

NA trial testing Fasting-Mimicking Diet in Non-small Cell Lung Cancer in 12 participants. Completed in 23 March 2022.

Timeline

2 November 2018

Primary endpoint
23 March 2022

23 March 2022

Quick facts

Lead sponsor	Indiana University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	12
Start date	2 November 2018
Primary completion	23 March 2022
Estimated completion	23 March 2022
Sites	3 locations across United States

Drugs / interventions tested

Fasting-Mimicking Diet

Conditions studied

Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →

Sponsor

Indiana University

Who can join

Adults 18 to 70, any sex, with Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to learn the effects of fasting on cancer cells while you get maintenance treatment.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Metabolic Regulation of Macrophage Polarization in Cancer.
Mehla K, Singh PK. · · 2019 · cited 470× · PMID 31813459 · DOI 10.1016/j.trecan.2019.10.007
Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer.
Vernieri C, Fucà G, Ligorio F, Huber V, et al · · 2022 · cited 249× · PMID 34789537 · DOI 10.1158/2159-8290.cd-21-0030
Effects of short-term fasting on cancer treatment.
de Groot S, Pijl H, van der Hoeven JJM, Kroep JR. · · 2019 · cited 87× · PMID 31113478 · DOI 10.1186/s13046-019-1189-9
Modulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy.
Kang X, Lau HC, Yu J. · · 2024 · cited 65× · PMID 38631285 · DOI 10.1016/j.xcrm.2024.101478
Nutrients in the Prevention of Alzheimer's Disease.
Cremonini AL, Caffa I, Cea M, Nencioni A, et al · · 2019 · cited 65× · PMID 31565158 · DOI 10.1155/2019/9874159
Targeting Glucose Metabolism to Enhance Immunotherapy: Emerging Evidence on Intermittent Fasting and Calorie Restriction Mimetics.
Turbitt WJ, Demark-Wahnefried W, Peterson CM, Norian LA. · · 2019 · cited 62× · PMID 31293576 · DOI 10.3389/fimmu.2019.01402
Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy.
Wu J, Wang S, Zheng B, Qiu X, et al · · 2021 · cited 49× · PMID 34267748 · DOI 10.3389/fimmu.2021.669150
Trial watch: dietary interventions for cancer therapy.
Lévesque S, Pol JG, Ferrere G, Galluzzi L, et al · · 2019 · cited 48× · PMID 31143510 · DOI 10.1080/2162402x.2019.1591878

Verify or expand the search:

Other trials of Fasting-Mimicking Diet

Trials testing the same drug.

NCT06831955 — LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer · Phase 2 · recruiting

Other recruiting trials for Non-small Cell Lung Cancer

Currently open trials in the same condition.

NCT07431827 — MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) · Phase 3 · recruiting
NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
NCT07195695 — Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
NCT06686771 — Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer · Phase 3 · recruiting
NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting

Other Indiana University trials

Trials by the same sponsor.

NCT07470086 — The Role of Environmental Temperatures in Respiratory Control · NA · not yet recruiting
NCT07470099 — The Role of Breathing Perception in Respiratory Control · NA · not yet recruiting
NCT07179952 — Efficacy and Safety of Slow Release Dehydroepiandrosterone (DHEA ) · Phase 2 · not yet recruiting
NCT07070804 — Maternal Biomarkers and Environmental Contributors to Autism Spectrum Disorders in Children of First-time Mothers · not yet recruiting
NCT07499583 — Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03700437 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Indiana University
Last refreshed: 12 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03700437.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing